

## **BELLA WANG**

Partner

Fangda Partners

+86 21 2208 5935

[Bella.wang@fangdalaw.com](mailto:Bella.wang@fangdalaw.com)



### **PRACTICE AREAS**

MS. WANG SPECIALIZES IN CORPORATE AND COMMERCIAL LAW, INCLUDING M&A, PRIVATE EQUITY AND REGULATORY AFFAIRS. SHE HAS A STRONG DEAL RECORD IN THE PHARMA, LIFE SCIENCE AND GENERAL INDUSTRY SECTORS.

### **REPRESENTATIVE MATTERS AND CASES**

- Represented AnHeart Therapeutics in granting a license to Innovent Biologics on the joint development and commercialization of AnHeart's major drug candidate, Taletrectinib
- Represented MitrAssist, a leading clinical stage medical device company offering innovative treatment for mitral regurgitation, in obtaining a license for heart-valve related technology and cooperation project
- Represented AstraZeneca in obtaining exclusive promotion rights from a leading foreign pharma company
- Represented AstraZeneca in granting to BioKangtai the exclusive license in China to AZD1222, an adenovirus vector-based COVID-19 vaccine
- Represented TopRidge Pharma in its in-license of the Sputnik-V vaccine developed in Russia
- Represented Eddingpharm in its pre-IPO reorganization and IPO on the main board of the Hong Kong Stock Exchange
- Represented Assembly Bio, Biogen, Cordis, CStone, Zai Lab, AnHeart, VISEN Pharmaceuticals and Virogin Biotech in general legal and compliance affairs, covering R&D projects, clinical trials, product distribution, product promotion, PAP, etc.
- Represented Sinopharm Capital in its equity investment transactions in the biotech and healthcare industries

- Represented Virogin Biotech in its Series C and Series D1 financing
- Represented IDG in its equity investment in the innovative online healthcare platform WEIMAI
- Represented BVCF in its equity investments in biotech companies
- Represented Covestro AG in acquiring a leading thin-film company in China
- Represented Wacker in its acquisition of a majority interest in a PRC company and in its cooperation with the PRC shareholders in the joint venture
- Represented Mount Kellett (now Fortress Investment) in its equity investment in and investment exit from a PRC real property brokerage company
- Represented E-Shang Redwood in its acquisitions and disposals of logistics property asset projects in China
- Represented LOGOS Logistics in its acquisitions of logistics property assets in China
- Represented City Developments Limited in its acquisition of property assets in China
- Represented Jingrui Holdings (01862.HK) in its joint venture projects with a leading US fund acquiring property in China
- Represented Johnson Matthey in its general legal and compliance affairs

## **OTHER INFORMATION**

### **Education**

- Boston University School of Law, LL.M. (2014)
- Shanghai University of Finance and Economics, School of Law, LL.B. (2011)

### **Professional Qualification**

- Admitted to practice in the PRC

### **Professional Background**

Ms. Wang joined Fangda as an associate in 2018. Before joining the firm, she worked for four years at another reputable law firm.